KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 76 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $825,058 | +16.1% | 47,499 | -5.9% | 0.00% | 0.0% |
Q2 2023 | $710,674 | +237.9% | 50,474 | +158.2% | 0.00% | +100.0% |
Q1 2023 | $210,304 | +15.4% | 19,545 | +60.7% | 0.00% | 0.0% |
Q4 2022 | $182,202 | -54.4% | 12,163 | -57.7% | 0.00% | -50.0% |
Q2 2021 | $400,000 | -57.4% | 28,744 | -45.8% | 0.00% | -71.4% |
Q4 2020 | $938,000 | +62.8% | 53,075 | +41.2% | 0.01% | -12.5% |
Q3 2020 | $576,000 | -1.9% | 37,591 | +63.2% | 0.01% | -11.1% |
Q2 2020 | $587,000 | +264.6% | 23,032 | +121.5% | 0.01% | +125.0% |
Q1 2020 | $161,000 | -87.9% | 10,399 | -91.4% | 0.00% | -50.0% |
Q4 2019 | $1,336,000 | +443.1% | 120,822 | +318.1% | 0.01% | +300.0% |
Q3 2019 | $246,000 | -52.7% | 28,896 | -24.8% | 0.00% | -60.0% |
Q2 2019 | $520,000 | +8.6% | 38,400 | +44.7% | 0.01% | 0.0% |
Q1 2019 | $479,000 | +15.7% | 26,540 | +79.9% | 0.01% | 0.0% |
Q4 2018 | $414,000 | +29.8% | 14,752 | +17.7% | 0.01% | +25.0% |
Q3 2018 | $319,000 | – | 12,529 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,025,000 | $12,064,000 | 2.56% |
GREAT POINT PARTNERS LLC | 536,738 | $6,317,000 | 1.40% |
Endurant Capital Management LP | 244,125 | $2,873,000 | 0.69% |
HHLR ADVISORS, LTD. | 2,920,023 | $34,369,000 | 0.53% |
Integral Health Asset Management, LLC | 140,000 | $1,648,000 | 0.46% |
Spearhead Capital Advisors, LLC | 235,024 | $2,766,000 | 0.33% |
Jackson Creek Investment Advisors LLC | 77,069 | $907,000 | 0.32% |
RICE HALL JAMES & ASSOCIATES, LLC | 712,807 | $8,390,000 | 0.30% |
Parkman Healthcare Partners LLC | 113,644 | $1,338,000 | 0.30% |
Birchview Capital, LP | 30,000 | $353,000 | 0.23% |